(Q34397646)

English

Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

type 2 diabetes

0 references

0 references

drug interaction

0 references

author name string

André J Scheen

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

publication date

1 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

53

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

295-304

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Oral antidiabetic agents. A guide to selection

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Oral Antidiabetic Agents

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Antihyperglycaemic agents. Drug interactions of clinical importance

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collab

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Drug interactions of clinical importance with antihyperglycaemic agents: an update

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Pharmacokinetic interactions with thiazolidinediones

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Drug-drug interactions with glucagon-like peptide-1 receptor agonists

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Management of type 2 diabetes: new and future developments in treatment

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Renal glucose reabsorption inhibitors to treat diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Dapagliflozin: a review of its use in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Canagliflozin: first global approval

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Impact of voglibose on the pharmacokinetics of dapagliflozin in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0128-8

21 January 2018

Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin

1 reference

https://pubmed.ncbi.nlm.nih.gov/24420910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/24420910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/24420910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytochrome P450-mediated cardiovascular drug interactions

1 reference

https://pubmed.ncbi.nlm.nih.gov/24420910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/24420910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin

1 reference

https://pubmed.ncbi.nlm.nih.gov/24420910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment

1 reference

https://pubmed.ncbi.nlm.nih.gov/24420910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduction of the acute bioavailability of metformin by the alpha-glucosidase inhibitor acarbose in normal man

1 reference

https://pubmed.ncbi.nlm.nih.gov/24420910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24420910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update

1 reference

https://pubmed.ncbi.nlm.nih.gov/24420910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40262-013-0128-8

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34397646&oldid=2196583674"